OR WAIT 15 SECS
Feliza Mirasol is the science editor for BioPharm International.
Single-use technologies have become increasingly prevalent in final fill/finish operations for biologics.
The increasing number of biologic drugs in development is driving the need for more efficient and cost-effective manufacturing technologies, including in single-use technologies for final fill/finish. Single-use technologies have become increasingly prevalent in fill/finish as a result of industry demand.
BioPharm Internationalspoke to BJ Hull, vice-president and general manager (Camden), Emergent BioSolutions; Sara Bell, senior marketing manager, Single-use Solutions, MilliporeSigma, a business of Merck KGaA, Darmstadt, Germany; and Claus Feussner, PhD, senior vice-president Vetter Development Service, Vetter Pharma-Fertigung, on the adoption, benefits, and challenges of single-use systems in final fill/finish manufacturing.
eBook: BioPharm International Single-Use Systems
When referring to this article, please cite it as F. Mirasol, “Single-Use Boosts Fill/Finish in Commercial Biomanufacturing,” BioPharm International Single-Use Systems eBook (June 2018).
Related Content:Formulation | Process Control, Automation, and PAT | Manufacturing | Manufacturing, Aseptic Processing | Manufacturing Systems, Single-Use | Facility Design and Engineering | Quality/GMPs | Manufacturing, Fill/Finish | Manufacturing Equipment, Biologics | Formulation and Drug Delivery, Biologic Drugs | Manufacturing, Biologics | Packaging, Labeling, and Distribution Systems | Manufacturing, Parenterals and Injectables | Quality Control/Quality Assurance